Aquinox and Neoleukin merge to develop immunotherapies
Public Vancouver-based biotech Aquinox Pharmaceuticals Inc. acquired Neoleukin Therapeutics Inc. (de novo protein design technology for cancer drug development) in a reverse merger through which Aquinox will assume the Neoleukin name and Neoleukin’s executive staff.
- Drug Discovery Tools
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.